You searched for stem cell biotech - Page 27 of 41

8 simple reasons not to get an unlicensed stem cell treatment part 2: lack of follow-up

November 15, 2012 / Professor Paul Knoepfler, Ph.D. / 2 Comments

I’m doing a series of posts on straightforward reasons why patients should not get unlicensed stem cell treatments. Part 1 of the series was on the risk of losing medical insurance coverage. Today is part 2, which is focused on a serious failing of many for-profit, point-of-care stem cell clinics selling unlicensed treatments: lack of […]

8 simple reasons not to get an unlicensed stem cell treatment part 2: lack of follow-up Read More »

Money and stem cell ‘miracles’: Pluristem questioned on ethics

November 8, 2012 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Pluristem Therapeutics Inc. is a publicly traded (NASDAQ) biotech Israeli company that is developing stem cell treatments based on the use of expanded placental stem cells called PLX cells. The Pluristem PLX drug is not approved for treating patients at this time in any country, however Pluristem has treated a handful of patients via something

Money and stem cell ‘miracles’: Pluristem questioned on ethics Read More »

Part 1 on iPS cell 2012 publication trends: an unusual year

September 20, 2012 / Professor Paul Knoepfler, Ph.D.

I regularly do an update on the publication trends in the iPS cell field and these have been posts that readers have found especially useful. Here was a popular update from 2010 and another one from 2011 that included a who’s who of the iPS cell field more broadly as well beyond just publishing. Then

Part 1 on iPS cell 2012 publication trends: an unusual year Read More »

Interesting new insights into Celltex’s business model

August 21, 2012 / Professor Paul Knoepfler, Ph.D.

The Texas stem cell clinic, Celltex, is lately becoming a model of transparency in the biotech industry. They are willing to answer many (if not all) questions I’ve been asking them. Celltex is involved in stem cell isolation and multiplication, and banking (see post here on the pros and cons of stem cell banking) as

Interesting new insights into Celltex’s business model Read More »

Eerie parallels between thalidomide & dubious stem cell treatments

August 16, 2012 / Professor Paul Knoepfler, Ph.D. / 3 Comments

I keep seeing these eerie parallels between thalidomide & dubious stem cell treatments. What’s the first rule of medicine again? Do no harm! Rushing new medicines such as stem cell treatments to patients without appropriate preliminary studies to try to make money is like playing Russian Roulette with patients. Some of the time, everything will

Eerie parallels between thalidomide & dubious stem cell treatments Read More »

Predictions heat up on FDA audit of Celltex

June 25, 2012 / Professor Paul Knoepfler, Ph.D.

Celltex is an adult stem cell company in the great state of Texas that reportedly has produced adult stem cell products used for the treatment of more than 100 patients with stem cells. We don’t know much about Celltex (e.g. it has no website), but I was hoping to change that in part via a

Predictions heat up on FDA audit of Celltex Read More »

The stem cell gestalt of Geron Goodbye and the future of ACT

June 22, 2012 / Professor Paul Knoepfler, Ph.D. / 6 Comments

Last year one of the biggest events in the stem cell field was biotech Geron punting its embryonic stem cell (ESC) program. Much consternation followed. Some folks opposed to ESCs happily pronounced ESC research dead. Some folks in favor of ESC thought the world was ending a year early. Others tried to look on the

The stem cell gestalt of Geron Goodbye and the future of ACT Read More »

TGIF: good, bad, ugly stem cell headlines of week of May 25

May 25, 2012 / Professor Paul Knoepfler, Ph.D. / 2 Comments

TGIF It’s been a wild week on this blog with many thoughts going out to the future of stem cells in Texas. What about stem cell headlines of the week? Some wildness there too and lots of discussion of translational applications, which is exciting. This week let’s start in reverse order with the ugly and

TGIF: good, bad, ugly stem cell headlines of week of May 25 Read More »

Centeno and Sipp interview on FDA stem cell oversight

May 1, 2012 / Professor Paul Knoepfler, Ph.D. / 34 Comments

I have interviewed two folks on the very important US vs. Regenerative Sciences legal case: Dr. Chris Centeno and Doug Sipp. More background on the case can be found at the FDA Law Blog. I thank them both for their time and for sharing their unique perspectives. I have specific rules for these interviews and

Centeno and Sipp interview on FDA stem cell oversight Read More »

Stem cells for eye disorders webinar: CIRM, ACT, and FDA together

May 1, 2012 / Professor Paul Knoepfler, Ph.D. / 2 Comments

Where do we stand on stem cells for eye disorders? The only biotech with an active hESC-based clinical trial, Advanced Cell Technology (ACT) will have three top leaders including CEO Gary Rabin participating in a CIRM webinar on stem cell-based treatments for eye disorders this Wednesday. Also involved with be Samuel Barone, a medical officer

Stem cells for eye disorders webinar: CIRM, ACT, and FDA together Read More »

Search Results for: stem cell biotech